Stockholder Alert: Robbins LLP Informs MoonLake Immunotherapeutics Stockholders that a Class Action Lawsuit was Filed Against the Company
MoonLake Immunotherapeutics(US:MLTX) Prnewswire·2025-10-16 10:27Accessibility StatementSkip Navigation SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Robbins LLPÂ informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025. MoonLake is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology. SOURCE Robbins LLP For more info ...